Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis

Sindet-Pedersen, Caroline; Pallisgaard, Jannik Langtved; Olesen, Jonas Bjerring; Gislason, Gunnar; Arevalo, Lourdes Cantarero

doi:10.1016/j.thromres.2015.07.022

Cited by 17 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral anticoagulants are the standard modality for the treatment of these conditions. Compared to placebo, there is an 83% decrease in the recurrence of VTE with warfarin or non-vitamin K oral anticoagulant (NOAC) therapy [ 9 ]. Likewise, warfarin reduces the risk of ischemic stroke by 60% in patients with AF [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey

et al. 2017

View full text Add to dashboard Cite

Background Guidelines on the management of orally anticoagulated patients are continuously evolving, leading to an increased need for pharmacists to be fully integrated in care provision. Objective To identify self-reported gaps in confidence among practicing pharmacists in the area of anticoagulation. Setting Pharmacists in different work settings in different countries. Method Cross-sectional international survey from October 2015 till November 2016 among pharmacists working in different settings to assess their level of confidence when delivering anticoagulants as well as to identify possible educational needs regarding this medication class. Validation of the survey was ensured. Results Responses from 4212 pharmacists originating from 18 countries were obtained. Pharmacists’ level of confidence was significantly higher (p < 0.001) when advising patients on vitamin K antagonists (VKAs) versus non-vitamin K antagonists (NOACs). In general, hospital pharmacists displayed higher confidence levels compared to community pharmacists when advising patients on anticoagulation (p < 0.001). Two distinct patterns of confidence levels emerged relating to basic and advanced pharmaceutical care. Confidence levels when providing advanced pharmaceutical care were significantly higher for Oceania and lower for South America (p < 0.005). Conclusions Pharmacists felt more confident in supporting patients receiving VKAs compared to the more recently introduced NOACs. With the increasing use of NOACs and the risks pertaining to anticoagulation therapy, it is essential to invest in education for pharmacists to address their knowledge gaps enabling them to confidently support patients receiving oral anticoagulants.Electronic supplementary materialThe online version of this article (10.1007/s11096-017-0551-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey

et al. 2017

View full text Add to dashboard Cite

show abstract

“…71,72 In contrast to the other 2 trials, the AMPLIFY-EXT trial compared 2 dosing regimens of apixaban (2.5 and 5 mg BID) with placebo to identify the dose providing the best balance of efficacy and safety. 69 The risk of recurrent VTE with the lower dose apixaban regimen was similar to that with the higher dose regimen (RR, 0.97; 95% CI, 0.46-2.02) and neither regimen was associated with a significant increase in major bleeding compared with placebo, but there was a trend for less clinically relevant bleeding with the lower dose regimen than with the higher dose regimen (RR, 0.74; 95% CI, 0.46-1.22).…”

Section: Doacs For Treatment Of Vtementioning

confidence: 99%

Evolving Treatments for Arterial and Venous Thrombosis

Chan

Eikelboom

Weitz

2016

Circulation Research

102

View full text Add to dashboard Cite

“…Unlike dabigatran, these agents are direct inhibitors to free and thrombus bound activated factor Xa (FXa). The attractiveness of the direct oral anticoagulants (DOACs) includes their predictable pharmacokinetics and noninferior outcomes when compared with traditional Coumadin or low molecular weight heparin (LMWH) therapies, with reported less incidence of intracranial bleeding . Manufacturer direct marketing strategy to consumers also emphasizes that with these new agents, there are no known dietary restrictions or interferences, and no routine monitoring required.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the effect of the anti‐Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays

Gosselin

Grant²,

Adcock

2016

Int J Lab Hematology

103

129

View full text Add to dashboard Cite

show abstract

Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis

Cited by 17 publications

References 33 publications

Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey

Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey

Evolving Treatments for Arterial and Venous Thrombosis

Comparison of the effect of the anti‐Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays

Contact Info

Product

Resources

About